^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Aybintio (bevacizumab biosimilar)

    i
    Other names: SB8, SP-8, 615
    Company:
    3SBio, Mundipharma, Samsung
    Drug class:
    VEGF-A inhibitor
    Related drugs:
    2d
    Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer (clinicaltrials.gov)
    P1/2, N=85, Recruiting, Mayo Clinic | Trial completion date: Feb 2028 --> Aug 2029 | Trial primary completion date: Aug 2027 --> Aug 2029
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    7d
    Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial (clinicaltrials.gov)
    P2, N=535, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Initiation date: Sep 2026 --> Apr 2026
    Enrollment open • Trial initiation date • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Avastin (bevacizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Krazati (adagrasib) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    14d
    Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial (clinicaltrials.gov)
    P3, N=226, Recruiting, NRG Oncology | Initiation date: Oct 2025 --> Feb 2026
    Trial initiation date
    |
    IL2 (Interleukin 2)
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • ABP 206 (nivolumab biosimilar)
    21d
    Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy (clinicaltrials.gov)
    P2, N=87, Not yet recruiting, National Cancer Institute (NCI)
    New P2 trial • Platinum sensitive
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
    |
    BRCA2 mutation • BRCA1 mutation • HRD
    |
    Avastin (bevacizumab) • carboplatin • gemcitabine • pegylated liposomal doxorubicin • Trodelvy (sacituzumab govitecan-hziy) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    2ms
    SWOG-S0518: Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor (clinicaltrials.gov)
    P3, N=427, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2026 --> Jan 2027
    Trial completion date
    |
    Avastin (bevacizumab) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Mycapssa (octreotide) • Avzivi (bevacizumab-tnjn) • Intron A (interferon α-2b) • Bioferon (interferon alpha 2b) • octreotide acetate
    2ms
    A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (clinicaltrials.gov)
    P2, N=88, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Mar 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    IL2 (Interleukin 2)
    |
    Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • gemcitabine • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    3ms
    Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (clinicaltrials.gov)
    P3, N=255, Recruiting, National Cancer Institute (NCI) | Initiation date: Oct 2026 --> Jan 2026
    Trial initiation date • pMMR
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • paclitaxel • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    3ms
    Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (clinicaltrials.gov)
    P3, N=255, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting | Initiation date: Mar 2026 --> Oct 2026
    Enrollment open • Trial initiation date • pMMR
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • paclitaxel • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    3ms
    Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial (clinicaltrials.gov)
    P3, N=252, Recruiting, NRG Oncology | Not yet recruiting --> Recruiting
    Enrollment open
    |
    IL2 (Interleukin 2)
    |
    Opdivo (nivolumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    4ms
    Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial (clinicaltrials.gov)
    P2, N=535, Not yet recruiting, City of Hope Medical Center
    New P2 trial • IO biomarker
    |
    Avastin (bevacizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Krazati (adagrasib) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    4ms
    Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (clinicaltrials.gov)
    P3, N=255, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Dec 2025 --> Mar 2026
    Trial initiation date • pMMR
    |
    TP53 mutation
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • paclitaxel • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)
    4ms
    Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov)
    P2, N=169, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Jan 2025
    Trial completion • Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF wild-type
    |
    Avastin (bevacizumab) • Yervoy (ipilimumab) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)